JP4641796B2 - Ａｋｔ阻害剤、医薬組成物、及びその用途 - Google Patents

Ａｋｔ阻害剤、医薬組成物、及びその用途 Download PDF

Info

Publication number
JP4641796B2
JP4641796B2 JP2004534522A JP2004534522A JP4641796B2 JP 4641796 B2 JP4641796 B2 JP 4641796B2 JP 2004534522 A JP2004534522 A JP 2004534522A JP 2004534522 A JP2004534522 A JP 2004534522A JP 4641796 B2 JP4641796 B2 JP 4641796B2
Authority
JP
Japan
Prior art keywords
akt
group
compound
pharmaceutical composition
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004534522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005537329A (ja
JP2005537329A5 (enExample
Inventor
コジカウスキー、アラン、ピー．
デニス、フィリップ
スン、ヘイイン
ブログナード、ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2005537329A publication Critical patent/JP2005537329A/ja
Publication of JP2005537329A5 publication Critical patent/JP2005537329A5/ja
Application granted granted Critical
Publication of JP4641796B2 publication Critical patent/JP4641796B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/196—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004534522A 2002-09-03 2003-09-03 Ａｋｔ阻害剤、医薬組成物、及びその用途 Expired - Fee Related JP4641796B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40723902P 2002-09-03 2002-09-03
PCT/US2003/027607 WO2004022569A1 (en) 2002-09-03 2003-09-03 Akt inhibitors, pharmaceutical compositions, and uses thereof

Publications (3)

Publication Number Publication Date
JP2005537329A JP2005537329A (ja) 2005-12-08
JP2005537329A5 JP2005537329A5 (enExample) 2006-10-12
JP4641796B2 true JP4641796B2 (ja) 2011-03-02

Family

ID=31978442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004534522A Expired - Fee Related JP4641796B2 (ja) 2002-09-03 2003-09-03 Ａｋｔ阻害剤、医薬組成物、及びその用途

Country Status (6)

Country Link
US (1) US7378403B2 (enExample)
EP (1) EP1537129B1 (enExample)
JP (1) JP4641796B2 (enExample)
AU (1) AU2003270087B2 (enExample)
CA (1) CA2497572C (enExample)
WO (1) WO2004022569A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101632669B (zh) * 2000-08-04 2011-05-18 Dmi生物科学公司 二酮基哌嗪和包含它们的组合物的使用方法
AU2003279761B2 (en) * 2002-10-02 2009-11-12 Luoxis Diagnostics, Inc. Diagnosis and monitoring of diseases
KR20150080004A (ko) 2003-05-15 2015-07-08 앰피오 파마슈티컬스 인코퍼레이티드 Ｔ-세포 매개성 질환의 치료 방법
WO2008070823A2 (en) * 2006-12-07 2008-06-12 University Of South Florida Substrate-mimetic akt inhibitor
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
JP2013537195A (ja) 2010-09-07 2013-09-30 ディエムアイ アクイジション コーポレイション 疾患の治療
AU2012323305B2 (en) 2011-10-10 2017-07-27 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
BR112014007657A2 (pt) 2011-10-10 2017-04-11 Ampio Pharmaceuticals Inc dispositivos médicos implantáveis com tolerância imune aperfeiçoada e métodos para produção e implantação
MX355446B (es) 2011-10-28 2018-04-18 Ampio Pharmaceuticals Inc Tratamiento de rinitis.
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
BR112015020469A2 (pt) 2013-03-15 2020-01-28 Ampio Pharmaceuticals Inc Usos de da-dkp, composição e método para fornecimento de células-tronco a umindivíduo
SG11201600525XA (en) 2013-08-12 2016-02-26 Tokai Pharmaceuticals Inc Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US10526660B2 (en) 2013-09-12 2020-01-07 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
CA2958080A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
HK1246669A1 (zh) 2015-06-22 2018-09-14 Ampio Pharmaceuticals, Inc. 人血清白蛋白低分子量组分在疾病治疗中的应用
WO2021118924A2 (en) 2019-12-12 2021-06-17 Ting Therapeutics Llc Compositions and methods for the prevention and treatment of hearing loss
CN111704546A (zh) * 2020-06-30 2020-09-25 海南师范大学 一种含氧环己烷衍生物及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585762A (en) * 1982-07-30 1986-04-29 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, processes for use thereof and pharmaceutical composition of the same
JPS59187786A (ja) * 1983-04-11 1984-10-24 Meito Sangyo Kk 酵素法リン脂質二級アルコ−ル誘導体の製法
EP0122151B1 (en) * 1983-04-11 1989-02-15 Meito Sangyo Kabushiki Kaisha Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique
US5227508A (en) 1992-01-24 1993-07-13 Mayo Foundation For Medical Education And Research 3-deoxy-3-substituted analogs of phosphatidylinositol
AU4427199A (en) * 1998-06-26 2000-01-17 Georgetown University Inhibitors of phosphatidyl (myo)-inositol cycle

Also Published As

Publication number Publication date
EP1537129B1 (en) 2013-11-06
WO2004022569A9 (en) 2004-06-10
JP2005537329A (ja) 2005-12-08
EP1537129A1 (en) 2005-06-08
AU2003270087A1 (en) 2004-03-29
AU2003270087B2 (en) 2009-04-23
CA2497572C (en) 2013-05-14
WO2004022569A1 (en) 2004-03-18
US7378403B2 (en) 2008-05-27
US20050272708A1 (en) 2005-12-08
CA2497572A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
JP4641796B2 (ja) Ａｋｔ阻害剤、医薬組成物、及びその用途
EP1163243B1 (en) Calanolides for inhibiting btk
TW202024023A (zh) 治療性化合物及其使用方法
US8283339B2 (en) Vinyl phosphonate lysophosphatidic acid receptor antagonists
Kwon et al. Synthesis and biological activity of cinnamaldehydes as angiogenesis inhibitors
RS52483B (sr) Derivati sulfonamida kao pro-lekovi inhibitora aspartil proteaze
CA3155989A1 (en) Therapeutic compounds and methods of use
AU2011292144B2 (en) 1,5-diphenyl-penta-1,4-dien-3-one compounds
WO2020007322A1 (zh) 一种靶向降解bet蛋白的化合物及其应用
US7153843B2 (en) Inhibitors of phosphatidyl myo-inositol cycle
US6245754B1 (en) Inhibitors of phosphatidyl myo-inositol cycle
US7550449B2 (en) Carba cyclic phosphatidic acid derivative
CA3090272A1 (en) Novel small molecule drug conjugates of gemcitabine derivatives
JP2009522212A (ja) ガン予防及び治療のためのＡｋｔ阻害剤としてのアリールジヒドロナフタレン類及びその生産方法
US20090221702A1 (en) Compounds
CN109206435B (zh) 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途
AU2004270473A1 (en) Calixarenes as inhibitors of protein kinase B
GB2579149A (en) Pharmaceutical composition for preventing or treating cancer containing receptor tyrosine kinase inhibitor as active ingredient
JP2008290956A (ja) 新規抗癌剤
HK1078586B (en) Carbacyclic phosphatidic acid derivative

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060828

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20091224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100401

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100506

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101006

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101102

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101130

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131210

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees